Free Trial
→ URGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW? (From Paradigm Press) (Ad) Buy AUTL Stock  Free AUTL Stock Alerts

Autolus Therapeutics (AUTL) Financials

Autolus Therapeutics logo
$1.75 +0.10 (+6.06%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.73 -0.02 (-1.37%)
As of 05/29/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Autolus Therapeutics

Annual Income Statements for Autolus Therapeutics

This table shows Autolus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 9/30/2018 9/30/2017 9/30/2016
Net Income / (Loss) Attributable to Common Shareholders		 -221 -208 -149 -145 -142 -124 -45 -19 -13
Consolidated Net Income / (Loss)		 -221 -208 -149 -142 -142 -124 -45 -20 -13
Net Income / (Loss) Continuing Operations		 -221 -208 -149 -142 -142 -124 -45 -20 -13
Total Pre-Tax Income 		-219 -208 -149 -142 -166 -139 -52 -23 -14
Total Operating Income		 -241 -180 -143 -141 -168 -146 -58 -23 -14
Total Gross Profit		 -1.27 1.70 6.36 2.33 1.72 2.91 1.41 1.69 1.21
Total Revenue		 10 1.70 6.36 2.33 1.72 2.91 1.41 1.69 1.21
Operating Revenue		 10 1.70 6.36 2.33 1.72 2.91 1.41 1.69 1.21
Total Cost of Revenue		 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 11 0.00 - - - - - - -
Total Operating Expenses		 240 181 150 143 170 149 59 25 16
Selling, General & Admin Expense		 101 47 32 32 35 39 23 9.10 5.15
Research & Development Expense		 138 130 117 111 135 105 36 16 10
Impairment Charge		 0.41 0.38 0.00 - - 4.10 0.00 0.00 -
Other Special Charges / (Income)		 0.22 3.79 0.52 0.68 0.00 0.00 - - -
Total Other Income / (Expense), net		 22 -29 -5.16 -1.98 1.89 7.06 5.50 0.08 0.05
Interest Expense		 9.29 45 8.91 1.11 0.00 0.00 - - -
Interest & Investment Income		 32 14 1.71 0.26 0.54 2.54 1.53 0.08 0.08
Other Income / (Expense), net		 -0.77 2.86 2.04 -1.13 1.35 4.51 3.97 -0.01 -0.03
Income Tax Expense		 1.53 -0.02 0.27 0.06 -24 -15 -7.28 -3.65 -1.78
Basic Earnings per Share		 ($0.86) ($1.20) ($1.57) ($1.97) ($2.76) ($2.88) ($1.42) ($1.43) ($1.26)
Weighted Average Basic Shares Outstanding		 255.16M 173.94M 94.99M 72.08M 51.56M 43.07M 31.56M 13.78M 9.93M
Diluted Earnings per Share		 ($0.86) ($1.20) ($1.57) ($1.97) ($2.76) ($2.88) ($1.42) ($1.43) ($1.26)
Weighted Average Diluted Shares Outstanding		 255.16M 173.94M 94.99M 72.08M 51.56M 43.07M 31.56M 13.78M 9.93M
Weighted Average Basic & Diluted Shares Outstanding		 266.13M 265.93M 173.07M 90.91M 51.56M 43.07M 31.56M 13.78M 9.93M

Quarterly Income Statements for Autolus Therapeutics

This table shows Autolus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -29 -82 -57 -53 -77 -46 -46 -40 -43
Consolidated Net Income / (Loss)		 -28 -82 -58 -53 -77 -46 -46 -40 -43
Net Income / (Loss) Continuing Operations		 -28 -82 -58 -53 -77 -46 -46 -40 -43
Total Pre-Tax Income 		-26 -82 -58 -53 -77 -46 -46 -40 -49
Total Operating Income		 -76 -68 -59 -39 -53 -43 -44 -39 -43
Total Gross Profit		 -11 0.00 0.00 10 - 0.41 0.00 1.29 2.37
Total Revenue		 0.03 0.00 0.00 10 - 0.41 0.00 1.29 2.37
Operating Revenue		 0.03 0.00 0.00 10 - 0.41 0.00 1.29 2.37
Total Cost of Revenue		 11 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 65 68 59 49 53 43 44 40 46
Selling, General & Admin Expense		 34 27 22 18 16 11 11 9.28 8.23
Research & Development Expense		 31 40 37 31 38 32 33 27 38
Total Other Income / (Expense), net		 49 -14 1.00 -14 -24 -2.97 -1.14 -0.68 -5.43
Interest Expense		 -31 11 10 19 30 5.01 5.02 4.91 1.85
Interest & Investment Income		 7.45 8.32 9.66 6.93 3.01 3.65 3.40 3.45 0.17
Other Income / (Expense), net		 11 -12 1.52 -1.61 3.19 -1.60 0.48 0.78 -3.74
Income Tax Expense		 1.46 0.02 0.05 -0.01 -0.02 -0.02 0.04 -0.01 -6.15
Basic Earnings per Share		 ($0.09) ($0.31) ($0.22) ($0.24) ($0.45) ($0.26) ($0.26) ($0.23) ($0.47)
Weighted Average Basic Shares Outstanding		 255.16M 266.08M 266.03M 222.17M 173.94M 173.98M 173.86M 173.83M 91.24M
Diluted Earnings per Share		 ($0.09) ($0.31) ($0.22) ($0.24) ($0.45) ($0.26) ($0.26) ($0.23) ($0.47)
Weighted Average Diluted Shares Outstanding		 255.16M 266.08M 266.03M 222.17M 173.94M 173.98M 173.86M 173.83M 91.24M
Weighted Average Basic & Diluted Shares Outstanding		 266.13M 266.12M 266.09M 266.04M 265.93M 173.99M - - -

Annual Cash Flow Statements for Autolus Therapeutics

This table details how cash moves in and out of Autolus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 9/30/2018 9/30/2017 9/30/2016
Net Change in Cash & Equivalents		 -12 -142 72 157 -57 -6.13 110 109 18
Net Cash From Operating Activities		 -206 -146 -112 -118 -118 -101 -32 -16 -9.85
Net Cash From Continuing Operating Activities		 -205 -146 -112 -118 -118 -101 -32 -16 -9.85
Net Income / (Loss) Continuing Operations		 -221 -208 -149 -142 -142 -124 -45 -20 -13
Consolidated Net Income / (Loss)		 -221 -208 -149 -142 -142 -124 -45 -20 -13
Depreciation Expense		 7.55 6.57 7.42 8.46 5.66 4.61 1.71 1.01 0.48
Amortization Expense		 0.16 0.00 - - - - - - -
Non-Cash Adjustments To Reconcile Net Income		 32 57 29 15 19 37 6.77 4.24 3.46
Changes in Operating Assets and Liabilities, net		 -24 -0.69 0.27 0.34 -0.10 -19 4.73 -1.88 -1.23
Net Cash From Investing Activities		 -395 -11 -11 -8.86 -15 -19 -9.53 -2.88 -1.86
Net Cash From Continuing Investing Activities		 -395 -11 -11 -8.86 -15 -19 -9.53 -2.88 -1.86
Purchase of Property, Plant & Equipment		 -22 -11 -11 -8.86 -15 -18 -9.12 -2.88 -1.86
Acquisitions		 -13 0.00 - - - -0.33 -0.41 0.00 0.00
Purchase of Investments		 -360 0.00 - - - - - - -
Net Cash From Financing Activities		 590 -0.88 224 284 74 109 157 128 32
Net Cash From Continuing Financing Activities		 590 -0.88 224 284 74 109 157 128 32
Repurchase of Common Equity		 -29 -0.91 -10 -11 -5.80 -7.10 - - -
Issuance of Common Equity		 550 0.00 164 246 80 116 157 128 32
Other Financing Activities, net		 69 0.03 70 50 0.46 0.04 - - -
Effect of Exchange Rate Changes		 -0.26 15 -28 -0.75 0.68 5.16 -5.83 0.56 -2.66
Cash Income Taxes Paid		 2.39 0.55 0.47 0.36 -20 1.54 - - -

Quarterly Cash Flow Statements for Autolus Therapeutics

This table details how cash moves in and out of Autolus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022
Net Change in Cash & Equivalents		 -430 -48 -53 519 -17 -51 -36 -39 219
Net Cash From Operating Activities		 -38 -77 -51 -41 -25 -40 -38 -42 -15
Net Cash From Continuing Operating Activities		 -37 -77 -51 -41 -25 -40 -38 -42 -15
Net Income / (Loss) Continuing Operations		 -28 -82 -58 -53 -77 -46 -46 -40 -27
Consolidated Net Income / (Loss)		 -28 -82 -58 -53 -77 -46 -46 -40 -27
Depreciation Expense		 1.92 1.94 1.90 1.81 1.78 1.38 1.51 1.90 1.65
Non-Cash Adjustments To Reconcile Net Income		 -8.31 1.58 14 24 27 15 5.31 9.14 4.75
Changes in Operating Assets and Liabilities, net		 -2.85 1.83 -8.84 -14 23 -11 0.58 -14 5.99
Net Cash From Investing Activities		 -384 -9.59 -0.84 -0.53 -1.48 -1.50 -4.39 -3.62 -0.63
Net Cash From Continuing Investing Activities		 -384 -9.59 -0.84 -0.53 -1.48 -1.50 -4.39 -3.62 -0.63
Purchase of Property, Plant & Equipment		 -11 -9.59 -0.84 -0.53 -1.48 -1.50 -4.39 -3.62 -0.63
Net Cash From Financing Activities		 30 0.19 -2.08 561 0.02 0.00 -0.22 -0.69 224
Net Cash From Continuing Financing Activities		 30 0.19 -2.08 561 0.02 0.00 -0.22 -0.69 224
Other Financing Activities, net		 30 0.19 -0.24 39 0.02 0.00 - 0.00 70
Effect of Exchange Rate Changes		 -38 38 1.42 -1.19 9.77 -9.30 7.23 7.33 11
Cash Income Taxes Paid		 1.13 0.28 - - 0.55 -0.27 - - -

Annual Balance Sheets for Autolus Therapeutics

This table presents Autolus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 9/30/2017
Total Assets		 783 375 490 406 294 304 254 149
Total Current Assets		 661 275 426 347 197 249 233 142
Cash & Equivalents		 227 240 382 310 153 211 217 137
Restricted Cash		 1.43 0.77 0.33 0.34 0.79 0.79 0.11 0.00
Short-Term Investments		 361 0.00 - - - - - -
Inventories, net		 4.14 0.00 - - - - - -
Prepaid Expenses		 67 35 43 36 43 38 15 5.41
Plant, Property, & Equipment, net		 50 35 35 34 38 28 20 6.18
Total Noncurrent Assets		 72 65 29 25 59 26 1.28 0.00
Intangible Assets		 12 0.00 - 0.07 0.16 0.25 0.00 0.00
Noncurrent Deferred & Refundable Income Taxes		 3.24 3.06 2.08 1.83 1.75 0.41 0.00 -
Other Noncurrent Operating Assets		 57 62 27 23 57 25 1.28 0.00
Total Liabilities & Shareholders' Equity		 783 375 490 406 294 304 254 149
Total Liabilities		 355 264 192 92 84 49 22 6.06
Total Current Liabilities		 61 45 46 29 34 25 21 5.03
Accounts Payable		 1.97 0.10 0.53 0.43 2.26 1.08 2.02 1.95
Accrued Expenses		 52 40 41 24 28 21 19 3.09
Current Deferred Revenue		 3.50 0.00 - - - - - -
Other Current Liabilities		 3.00 5.05 5.04 4.45 3.59 2.51 0.00 -
Total Noncurrent Liabilities		 295 219 145 64 51 24 0.49 1.03
Noncurrent Deferred Revenue		 245 171 126 47 0.00 - - -
Other Noncurrent Operating Liabilities		 50 48 19 17 51 24 0.21 0.27
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - - -
Total Equity & Noncontrolling Interests		 427 111 299 313 210 255 233 143
Total Preferred & Common Equity		 427 111 299 313 210 255 233 143
Total Common Equity		 427 111 299 313 210 255 233 143
Common Stock		 1,556 1,019 1,008 843 595 501 361 194
Retained Earnings		 -1,099 -879 -670 -521 -379 -237 -113 -48
Accumulated Other Comprehensive Income / (Loss)		 -29 -29 -39 -8.57 -5.86 -8.69 -15 -3.85

Quarterly Balance Sheets for Autolus Therapeutics

This table presents Autolus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023
Total Assets		 827 854 901 406
Total Current Assets		 718 759 804 308
Cash & Equivalents		 657 706 759 256
Restricted Cash		 1.47 1.02 1.02 0.43
Prepaid Expenses		 60 52 45 52
Plant, Property, & Equipment, net		 44 33 33 35
Total Noncurrent Assets		 65 62 64 63
Noncurrent Deferred & Refundable Income Taxes		 3.39 3.22 3.30 2.60
Other Noncurrent Operating Assets		 62 59 60 60
Total Liabilities & Shareholders' Equity		 827 854 901 406
Total Liabilities		 351 326 319 226
Total Current Liabilities		 52 41 44 38
Accounts Payable		 1.42 1.10 1.40 0.66
Accrued Expenses		 47 36 38 31
Other Current Liabilities		 3.57 4.23 4.82 5.49
Total Noncurrent Liabilities		 298 285 275 188
Noncurrent Deferred Revenue		 249 239 228 141
Other Noncurrent Operating Liabilities		 49 46 47 47
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 477 528 582 181
Total Preferred & Common Equity		 477 528 582 181
Total Common Equity		 477 528 582 181
Common Stock		 1,549 1,545 1,542 1,016
Retained Earnings		 -1,072 -990 -931 -801
Accumulated Other Comprehensive Income / (Loss)		 -0.90 -28 -29 -34

Annual Metrics And Ratios for Autolus Therapeutics

This table displays calculated financial ratios and metrics derived from Autolus Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 9/30/2018 9/30/2017 9/30/2016
Growth Metrics		 - - - - - - - - -
Revenue Growth		 496.00% -73.30% 172.96% 35.86% -41.02% 106.68% -16.89% 39.69% 0.00%
EBITDA Growth		 -37.71% -27.12% -0.17% 17.01% -17.67% -164.09% -131.32% -61.00% 0.00%
EBIT Growth		 -36.96% -25.09% 0.57% 14.75% -17.83% -164.27% -128.65% -62.66% 0.00%
NOPAT Growth		 -34.35% -25.31% -1.67% 16.11% -15.12% -153.88% -145.68% -62.90% 0.00%
Net Income Growth		 -5.89% -40.01% -4.75% 0.00% -14.73% -176.75% -126.85% -57.19% 0.00%
EPS Growth		 28.33% 23.57% 20.30% 28.62% 4.17% -102.82% 0.70% -13.49% 0.00%
Operating Cash Flow Growth		 -41.68% -29.63% 4.71% -0.09% -16.04% -221.79% -92.77% -66.11% 0.00%
Free Cash Flow Firm Growth		 -67.54% -493.33% 69.95% 65.12% 0.03% -163.99% -117.53% 0.00% 0.00%
Invested Capital Growth		 -25.81% -53.25% -3,280.30% -95.27% 28.88% 182.39% 144.23% 0.00% 0.00%
Revenue Q/Q Growth		 0.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -6.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -10.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 18.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 29.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -6.78% -7.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 10.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 -12.52% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,316.99% -10,027.97% -2,106.10% -5,739.27% -9,395.63% -4,709.04% -3,685.43% -1,324.10% -1,148.84%
Operating Margin		 -2,385.63% -10,583.10% -2,254.84% -6,053.65% -9,804.37% -5,022.83% -4,089.05% -1,383.23% -1,186.14%
EBIT Margin		 -2,393.23% -10,414.61% -2,222.80% -6,102.27% -9,725.54% -4,867.61% -3,806.89% -1,383.70% -1,188.28%
Profit (Net Income) Margin		 -2,180.45% -12,272.26% -2,340.24% -6,098.54% -8,285.36% -4,258.91% -3,180.60% -1,165.21% -1,035.48%
Tax Burden Percent		 100.70% 99.99% 100.18% 100.04% 85.47% 89.09% 86.01% 84.38% 87.60%
Interest Burden Percent		 90.48% 117.85% 105.09% 99.90% 99.68% 98.20% 97.14% 99.80% 99.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -337.03% -236.93% -347.88% -371.76% -520.90% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -318.37% -223.58% -337.80% -369.23% -516.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 282.73% 175.80% 297.07% 347.91% 493.23% 0.00%
Return on Equity (ROE)		 -81.91% -101.61% -48.64% -54.30% -61.13% -50.81% -23.85% -27.67% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -155.08% -262.17% -443.28% -455.56% -720.90% 0.00%
Operating Return on Assets (OROA)		 -41.83% -40.86% -31.56% -40.64% -55.81% -50.76% -26.59% -15.76% 0.00%
Return on Assets (ROA)		 -38.11% -48.14% -33.23% -40.61% -47.54% -44.41% -22.22% -13.27% 0.00%
Return on Common Equity (ROCE)		 -81.91% -101.61% -48.64% -54.30% -61.13% -50.81% -23.85% -27.67% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -51.64% -186.93% -49.83% -45.35% -67.65% -48.60% -19.24% -13.83% 0.00%
Net Operating Profit after Tax (NOPAT)		 -169 -126 -100 -99 -118 -102 -40 -16 -10
NOPAT Margin		 -1,669.94% -7,408.17% -1,578.39% -4,237.55% -6,863.06% -3,515.98% -2,862.34% -968.26% -830.30%
Net Nonoperating Expense Percent (NNEP)		 -12.45% -26.51% -13.97% -18.66% -13.35% -10.08% -2.53% -4.89% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -39.55% -112.84% - - - - - - -
Cost of Revenue to Revenue		 112.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 998.87% 2,752.94% 501.56% 1,367.60% 2,039.18% 1,356.67% 1,619.76% 537.45% 425.08%
R&D to Revenue		 1,367.94% 7,684.39% 1,845.19% 4,757.04% 7,865.19% 3,625.10% 2,569.30% 945.78% 861.06%
Operating Expenses to Revenue		 2,373.11% 10,683.10% 2,354.84% 6,153.65% 9,904.37% 5,122.83% 4,189.05% 1,483.23% 1,286.14%
Earnings before Interest and Taxes (EBIT)		 -242 -177 -141 -142 -167 -142 -54 -23 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -234 -170 -134 -134 -161 -137 -52 -22 -14
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 1.46 10.05 0.58 0.87 1.91 2.08 1.16 1.05 0.00
Price to Tangible Book Value (P/TBV)		 1.51 10.05 0.58 0.87 1.92 2.08 1.16 1.05 0.00
Price to Revenue (P/Rev)		 61.80 659.89 27.16 116.60 234.49 182.23 192.34 88.60 123.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 4.43 7.34 3.47 2.18 0.00
Enterprise Value to Revenue (EV/Rev)		 3.55 518.35 0.00 0.00 144.64 109.52 37.92 8.09 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00
Financial Leverage		 -1.54 -1.52 -1.13 -0.89 -0.79 -0.88 -0.94 -0.96 0.00
Leverage Ratio		 2.15 2.11 1.46 1.34 1.29 1.14 1.07 1.04 0.00
Compound Leverage Factor		 1.94 2.49 1.54 1.34 1.28 1.12 1.04 1.04 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.53% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.12% 0.53% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.88% 99.47% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.03 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 4.19 6.08 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.03 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.05 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 5.39 8.32 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.05 0.00
Altman Z-Score		 -1.00 -1.54 -1.38 -0.24 -0.14 4.79 7.21 15.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 10.88 6.15 9.18 12.15 5.86 9.98 11.05 28.31 0.00
Quick Ratio		 9.68 5.36 8.25 10.87 4.56 8.43 10.32 27.23 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -136 -81 -14 -45 -130 -130 -49 -23 0.00
Operating Cash Flow to CapEx		 -934.41% -1,325.20% -1,035.96% -1,330.71% -802.11% -553.32% -345.84% -568.85% -530.94%
Free Cash Flow to Firm to Interest Expense		 -14.60 -1.80 -1.53 -41.11 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -22.19 -3.23 -12.61 -106.66 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -24.57 -3.47 -13.83 -114.68 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.24 0.05 0.19 0.07 0.05 0.12 0.11 0.27 0.00
Accounts Payable Turnover		 10.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 33.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -33.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -162 -129 -84 2.64 56 43 15 6.29 0.00
Invested Capital Turnover		 -0.07 -0.02 -0.16 0.08 0.03 0.10 0.13 0.54 0.00
Increase / (Decrease) in Invested Capital		 -33 -45 -87 -53 13 28 9.08 6.29 0.00
Enterprise Value (EV)		 36 880 -210 -39 248 318 53 14 0.00
Market Capitalization		 625 1,120 173 272 402 530 271 150 150
Book Value per Share		 $1.61 $0.64 $3.29 $5.99 $4.67 $6.35 $7.37 $10.35 $0.00
Tangible Book Value per Share		 $1.56 $0.64 $3.29 $5.98 $4.67 $6.34 $7.37 $10.35 $0.00
Total Capital		 427 111 299 313 210 255 233 143 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.76 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.76 0.00
Net Debt		 -589 -240 -383 -311 -154 -211 -217 -136 0.00
Capital Expenditures (CapEx)		 22 11 11 8.86 15 18 9.12 2.88 1.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 -9.77 -3.36 7.73 9.27 13 -5.67 0.38 0.00
Debt-free Net Working Capital (DFNWC)		 600 231 379 318 163 224 212 137 0.00
Net Working Capital (NWC)		 600 231 379 318 163 224 212 137 0.00
Net Nonoperating Expense (NNE)		 52 83 48 43 24 22 4.48 3.33 2.49
Net Nonoperating Obligations (NNO)		 -589 -240 -383 -311 -154 -211 -217 -136 0.00
Total Depreciation and Amortization (D&A)		 7.72 6.57 7.42 8.46 5.66 4.61 1.71 1.01 0.48
Debt-free, Cash-free Net Working Capital to Revenue		 106.11% -575.38% -52.77% 331.55% 540.23% 441.61% -402.63% 22.39% 0.00%
Debt-free Net Working Capital to Revenue		 5,930.69% 13,578.62% 5,965.49% 13,665.28% 9,524.78% 7,712.24% 15,059.70% 8,118.67% 0.00%
Net Working Capital to Revenue		 5,930.69% 13,578.62% 5,965.49% 13,665.28% 9,524.78% 7,712.24% 15,059.70% 8,118.67% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.86) ($1.20) ($1.57) ($1.97) ($2.76) ($2.88) ($1.42) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 255.16M 173.94M 94.99M 72.08M 52.35M 44.98M 40.15M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($0.86) ($1.20) ($1.57) ($1.97) ($2.76) ($2.88) ($1.42) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 255.16M 173.94M 94.99M 72.08M 52.35M 44.98M 40.15M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($2.76) ($2.88) ($1.42) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 266.13M 265.93M 173.07M 90.91M 51.56M 43.07M 31.56M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -169 -123 -100 -98 -118 -99 -40 -16 -10
Normalized NOPAT Margin		 -1,665.54% -7,236.14% -1,572.72% -4,217.24% -6,863.06% -3,417.24% -2,862.34% -968.26% -830.30%
Pre Tax Income Margin		 -2,165.36% -12,273.38% -2,335.96% -6,096.05% -9,694.29% -4,780.19% -3,698.01% -1,380.98% -1,182.10%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -26.06 -3.92 -15.88 -128.67 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -18.18 -2.79 -11.27 -89.35 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -28.43 -4.17 -17.09 -136.69 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -20.56 -3.04 -12.49 -97.37 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -13.31% -0.44% -6.96% -8.06% -4.08% -5.73% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Autolus Therapeutics

This table displays calculated financial ratios and metrics derived from Autolus Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 681.04% 0.00% -82.86% 0.00% 0.00% 0.00%
EBITDA Growth		 -30.02% -80.34% -30.98% -5.73% 0.00% 8.70% 0.00% 0.00% 0.00%
EBIT Growth		 -29.24% -79.11% -30.79% -5.20% 0.00% 5.78% 0.00% 0.00% 0.00%
NOPAT Growth		 -42.41% -58.20% -32.79% 1.00% 0.00% 1.35% 0.00% 0.00% 0.00%
Net Income Growth		 64.23% -79.05% -27.92% -32.35% 0.00% -7.21% 0.00% 0.00% 0.00%
EPS Growth		 80.00% -19.23% 15.38% -4.35% 0.00% 44.68% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -52.76% -90.95% -33.91% 4.49% -70.49% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Growth		 0.00% 24.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 -25.81% -137.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 19.24% -40.09% -43.98% 0.00% -12.01% -1.75% -16.22% 0.00% 0.00%
EBIT Q/Q Growth		 18.80% -38.84% -42.24% 0.00% -12.53% -1.38% -14.41% 0.00% 0.00%
NOPAT Q/Q Growth		 -11.77% -15.18% -52.05% 0.00% -24.16% 3.32% -13.36% 0.00% 0.00%
Net Income Q/Q Growth		 66.37% -40.88% -10.59% 0.00% -68.32% -0.65% -14.42% 0.00% 0.00%
EPS Q/Q Growth		 70.97% -40.91% 8.33% 0.00% -73.08% 0.00% -13.04% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 50.57% -50.23% -26.09% -63.15% 38.21% -5.35% 10.07% -191.22% 0.00%
Free Cash Flow Firm Q/Q Growth		 -134.37% -58.13% -8.32% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 10.71% -1.37% -0.90% 0.00% -68.82% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 -39,165.52% 0.00% 0.00% 100.00% 0.00% 100.00% 0.00% 100.00% 100.00%
EBITDA Margin		 -216,562.07% 0.00% 0.00% -382.08% 0.00% -10,621.43% 0.00% -2,822.52% -1,993.84%
Operating Margin		 -261,600.00% 0.00% 0.00% -384.07% 0.00% -10,567.73% 0.00% -3,030.03% -1,835.96%
EBIT Margin		 -223,165.52% 0.00% 0.00% -399.98% 0.00% -10,961.08% 0.00% -2,969.50% -1,993.84%
Profit (Net Income) Margin		 -95,193.10% 0.00% 0.00% -522.15% 0.00% -11,292.86% 0.00% -3,081.35% -1,805.28%
Tax Burden Percent		 105.60% 100.03% 100.09% 99.98% 99.97% 99.95% 100.09% 99.96% 87.42%
Interest Burden Percent		 40.40% 102.97% 101.41% 130.56% 154.15% 103.07% 103.68% 103.80% 103.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -81.91% -82.20% -44.33% -38.02% -101.61% 0.00% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -3,900.22% 0.00% 0.00% -4.66% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -1,663.67% 0.00% 0.00% -6.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -81.91% -82.20% -44.33% -38.02% -101.61% 0.00% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -56.66% -44.33% -38.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -53 -48 -41 -27 -37 -30 -31 -27 -30
NOPAT Margin		 -183,120.00% 0.00% 0.00% -268.85% 0.00% -7,397.41% 0.00% -2,121.02% -1,285.18%
Net Nonoperating Expense Percent (NNEP)		 6.15% -7.56% -4.82% -6.73% -16.59% -12.32% 0.00% 0.00% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -12.43% - - - -33.45% - - - -
Cost of Revenue to Revenue		 39,265.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 116,124.14% 0.00% 0.00% 180.13% 0.00% 2,613.55% 0.00% 718.58% 347.45%
R&D to Revenue		 106,310.34% 0.00% 0.00% 303.94% 0.00% 7,960.10% 0.00% 2,119.81% 1,588.52%
Operating Expenses to Revenue		 223,862.07% 0.00% 0.00% 484.07% 0.00% 10,667.73% 0.00% 3,130.03% 1,935.96%
Earnings before Interest and Taxes (EBIT)		 -65 -80 -57 -40 -50 -45 -44 -38 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -63 -78 -56 -39 -48 -43 -42 -36 -47
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 1.46 2.03 1.75 2.92 10.05 2.23 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 1.51 2.03 1.75 2.92 10.05 2.23 0.00 0.00 0.00
Price to Revenue (P/Rev)		 61.80 95.72 88.20 161.63 659.89 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.55 30.46 20.85 89.27 518.35 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.54 -1.39 -1.34 -1.31 -2.16 -1.42 0.00 0.00 0.00
Leverage Ratio		 2.15 1.88 1.62 1.55 2.11 2.25 0.00 0.00 0.00
Compound Leverage Factor		 0.87 1.93 1.64 2.02 3.25 2.32 0.00 0.00 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.25 0.50 0.88 2.62 -0.43 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 10.88 13.69 18.55 18.29 6.15 8.21 0.00 0.00 0.00
Quick Ratio		 9.68 12.52 17.26 17.25 5.36 6.83 0.00 0.00 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 58 138 150 0.00 46 0.00 0.00 0.00
Operating Cash Flow to CapEx		 -341.38% -800.29% -6,074.08% -7,601.13% -1,681.31% -2,682.78% -869.15% -1,171.15% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 5.40 13.55 7.80 0.00 9.23 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -7.18 -5.02 -2.10 -0.82 -8.02 -7.60 -8.65 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -8.08 -5.10 -2.13 -0.87 -8.31 -8.47 -9.39 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.02 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.24 0.26 0.32 0.31 0.05 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 10.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 33.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -33.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -162 -182 -179 -178 -129 -76 0.00 0.00 0.00
Invested Capital Turnover		 -0.07 -0.08 -0.12 -0.12 -0.01 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -33 -105 -179 -178 0.00 -76 0.00 0.00 0.00
Enterprise Value (EV)		 36 307 219 937 880 146 0.00 0.00 0.00
Market Capitalization		 625 966 926 1,697 1,120 403 412 318 195
Book Value per Share		 $1.61 $1.79 $1.98 $2.19 $0.64 $1.04 $0.00 $0.00 $0.00
Tangible Book Value per Share		 $1.56 $1.79 $1.98 $2.19 $0.64 $1.04 $0.00 $0.00 $0.00
Total Capital		 427 477 528 582 111 181 0.00 0.00 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -589 -659 -707 -760 -240 -257 0.00 0.00 0.00
Capital Expenditures (CapEx)		 11 9.59 0.84 0.53 1.48 1.50 4.39 3.62 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 7.10 11 0.77 -9.77 14 0.00 0.00 0.00
Debt-free Net Working Capital (DFNWC)		 600 666 718 760 231 271 0.00 0.00 0.00
Net Working Capital (NWC)		 600 666 718 760 231 271 0.00 0.00 0.00
Net Nonoperating Expense (NNE)		 -25 35 17 26 40 16 14 12 12
Net Nonoperating Obligations (NNO)		 -589 -659 -707 -760 -240 -257 0.00 0.00 0.00
Total Depreciation and Amortization (D&A)		 1.92 1.94 1.90 1.81 1.78 1.38 1.51 1.90 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 106.11% 70.39% 102.29% 7.33% -575.38% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 5,930.69% 6,596.37% 6,837.15% 7,243.15% 13,578.62% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 5,930.69% 6,596.37% 6,837.15% 7,243.15% 13,578.62% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.09) ($0.31) ($0.22) ($0.24) ($0.45) ($0.26) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 255.16M 266.08M 266.03M 222.17M 173.94M 173.98M 0.00 0.00 0.00
Adjusted Diluted Earnings per Share		 ($0.09) ($0.31) ($0.22) ($0.24) ($0.45) ($0.26) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 255.16M 266.08M 266.03M 222.17M 173.94M 173.98M 0.00 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 266.13M 266.12M 266.09M 266.04M 265.93M 173.99M 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -53 -47 -41 -27 -37 -30 -31 -25 -30
Normalized NOPAT Margin		 -183,120.00% 0.00% 0.00% -268.85% 0.00% -7,331.55% 0.00% -1,916.87% -1,285.18%
Pre Tax Income Margin		 -90,148.28% 0.00% 0.00% -522.23% 0.00% -11,298.03% 0.00% -3,082.43% -2,064.96%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 -7.46 -5.64 -2.09 -1.66 -8.88 -8.74 -7.82 -25.53
NOPAT to Interest Expense		 0.00 -4.45 -4.05 -1.41 -1.24 -5.99 -6.19 -5.59 -16.46
EBIT Less CapEx to Interest Expense		 0.00 -8.36 -5.73 -2.12 -1.71 -9.17 -9.62 -8.56 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -5.34 -4.14 -1.44 -1.29 -6.29 -7.06 -6.33 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -13.31% -10.86% -12.55% -12.54% -0.44% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Autolus Therapeutics' Financials

When does Autolus Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Autolus Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Autolus Therapeutics' net income changed over the last 8 years?

Autolus Therapeutics' net income appears to be on an upward trend, with a most recent value of -$220.66 million in 2024, rising from -$12.55 million in 2016. The previous period was -$208.38 million in 2023. See Autolus Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Autolus Therapeutics's operating income?
Autolus Therapeutics's total operating income in 2024 was -$241.43 million, based on the following breakdown:
  • Total Gross Profit: -$1.27 million
  • Total Operating Expenses: $240.16 million
How has Autolus Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Autolus Therapeutics' total revenue changed from $1.21 million in 2016 to $10.12 million in 2024, a change of 735.0%.

How much debt does Autolus Therapeutics have?

Autolus Therapeutics' total liabilities were at $355.40 million at the end of 2024, a 34.7% increase from 2023, and a 5,763.7% increase since 2017.

How much cash does Autolus Therapeutics have?

In the past 7 years, Autolus Therapeutics' cash and equivalents has ranged from $137.07 million in 2017 to $382.44 million in 2022, and is currently $227.38 million as of their latest financial filing in 2024.

How has Autolus Therapeutics' book value per share changed over the last 8 years?

Over the last 8 years, Autolus Therapeutics' book value per share changed from 0.00 in 2016 to 1.61 in 2024, a change of 160.6%.


Related Companies

This page (NASDAQ:AUTL) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners
Buffett’s Next Move Could Shock Wall Street
In just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...
Golden Portfolio | Sponsored
Elon Musk’s Frightening Warning Forces Trump’s Hand
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Urgent: Make this trade before you hit your pillow tonight…
Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...
Timothy Sykes | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored